[Congressional Record Volume 153, Number 72 (Thursday, May 3, 2007)]
[House]
[Pages H4461-H4464]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
TECHNOLOGY INNOVATION AND MANUFACTURING STIMULATION ACT OF 2007
The SPEAKER pro tempore. Pursuant to House Resolution 350 and rule
XVIII, the Chair declares the House in the Committee of the Whole House
on the state of the Union for the further consideration of the bill,
H.R. 1868.
{time} 1426
In the Committee of the Whole
Accordingly, the House resolved itself into the Committee of the
Whole House on the state of the Union for the further consideration of
the bill (H.R. 1868) to authorize appropriations for the National
Institute of Standards and Technology for fiscal years 2008, 2009, and
2010, and for other purposes, with Mrs. Tauscher (Acting Chairman) in
the chair.
The Clerk read the title of the bill.
The Acting CHAIRMAN. When the Committee of the Whole rose earlier
today, amendment No. 3 offered by the gentleman from Illinois (Mr.
Manzullo) had been disposed of.
Amendment No. 2 Offered by Mr. Wynn
The Acting CHAIRMAN. It is now in order to consider amendment No. 2
printed in House Report 110-118.
Mr. WYNN. Madam Chairman, I offer an amendment.
The Acting CHAIRMAN. The Clerk will designate the amendment.
The text of the amendment is as follows:
Amendment No. 2 offered by Mr. Wynn:
In section 204, in the proposed section 28(b)(1), insert
``(including any technological application that uses
biological systems, living organisms, or derivatives thereof,
to make or modify products or processes for specific use)''
after ``enabling technologies''.
The Acting CHAIRMAN. Pursuant to House Resolution 350, the gentleman
from Maryland (Mr. Wynn) and a Member opposed each will control 5
minutes.
The Chair recognizes the gentleman from Maryland.
Mr. WYNN. Madam Chair, the amendment that I am proposing will make
sure that the biotechnology research and innovation are included under
TIP's funding objectives by expanding the definition of enabling
technologies in section 204 of the bill to include ``any technological
application that uses biological systems, living organisms or
derivatives thereof to make or modify products or processes for
specific use.''
Biotechnology is an emerging segment of the technology sector often
overlooked as an excellent source of manufacturing jobs and research
and development. The biotechnology industry is a driving force in the
Maryland economy and a rising sector of the American economy.
In the United States, the biotechnology industry has created more
than 200 new therapies and vaccines, including products to treat
cancer, diabetes, HIV/AIDS and anti-autoimmune disorders.
The industry continues to develop innovative therapies over 400
products are currently in clinical trials targeting over 200 diseases.
The biotechnology industry is comprised of mostly small start-ups that
don't have an existing stream of revenue and are years away from
product commercialization. It takes at least 8 years, and then up to
$1.2 billion to get a biotechnology therapy approved.
It is these small companies, many of which will never see a product
come to market or turn a product that are undertaking the bulk of early
development gambles and working toward innovative cures. In fact, small
biotech companies account for two-thirds of the industry's pipeline.
In 2005, there were 1,400 biotech companies in the United States, but
only 329 were publicly traded. The majority of the Biotechnology
Industry Organization's (BIO) members are small companies that have
fewer than 50 employees.
The U.S. is the leader in biotechnology. The number of products in
the late stage pipeline in the U.S. has double the number of products
in the E.U. This is largely due to the fact that per capita biotech R&D
in the U.S. is 574 percent higher than in the E.U.
{time} 1430
My State of Maryland is a leader among States in biotechnology
research and innovation, and Maryland-based businesses will benefit
greatly from the funding awarded under this bill. But not only
Maryland; other small startup companies in the biotech industry will
benefit by inclusion of this bill.
I believe it is a simple, straightforward amendment that just expands
and clarifies the fact that biotechnology companies should be included,
and I ask support for the amendment.
Mr. WU. Madam Chairman, will the gentleman yield?
Mr. WYNN. I would be happy to yield.
Mr. WU. Madam Chairman, on the Science and Technology Committee we
are keenly aware of the importance of the biotechnology industry to our
economy. We also know that the
[[Page H4462]]
growth in our biotech industry is largely due to early Federal
investment and support in this field, and I am pleased to support the
gentleman from Maryland's amendment.
Mr. WYNN. Madam Chairman, I thank the chairman for his support.
Madam Chairman, I yield back the balance of my time.
Mr. EHLERS. Madam Chairman, I rise to say I have no objection to the
amendment, and I yield back the balance of my time.
The Acting CHAIRMAN. The question is on the amendment offered by the
gentleman from Maryland (Mr. Wynn).
The amendment was agreed to.
The Acting CHAIRMAN. The question is on the committee amendment in
the nature of a substitute, as amended.
The committee amendment in the nature of a substitute, as amended,
was agreed to.
The Acting CHAIRMAN. Under the rule, the Committee rises.
Accordingly, the Committee rose; and the Speaker pro tempore (Mr.
Scott of Virginia) having assumed the chair, Mrs. Tauscher, Acting
Chairman of the Committee of the Whole House on the state of the Union,
reported that that Committee, having had under consideration the bill
(H.R. 1868) to authorize appropriations for the National Institute of
Standards and Technology for fiscal years 2008, 2009, and 2010, and for
other purposes, pursuant to House Resolution 350, she reported the bill
back to the House with an amendment adopted by the Committee of the
Whole.
The SPEAKER pro tempore. Under the rule, the previous question is
ordered.
Is a separate vote demanded on any amendment to the amendment
reported from the Committee of the Whole? If not, the question is on
the amendment.
The amendment was agreed to.
The SPEAKER pro tempore. The question is on the engrossment and third
reading of the bill.
The bill was ordered to be engrossed and read a third time, and was
read the third time.
Motion to Recommit Offered by Mr. English of Pennsylvania
Mr. ENGLISH of Pennsylvania. Mr. Speaker, I offer a motion to
recommit.
The SPEAKER pro tempore. Is the gentleman opposed to the bill?
Mr. ENGLISH of Pennsylvania. In its present form, I am.
The SPEAKER pro tempore. The Clerk will report the motion to
recommit.
The Clerk read as follows:
Mr. English of Pennsylvania moves to recommit the bill H.R.
1868 to the Committee on Science and Technology with
instructions to report back the same forthwith with an
amendment. The amendment is as follows:
In section 204, insert ``(a) Amendment.--'' before
``Section 28 of''.
In section 204, add at the end the following new
subsection:
(b) Limiting Authorizations in Any Year Following a Year
With an On-Budget (excluding Social Security) Deficit and an
Off-Budget (Social Security) Surplus.--
(1) Limitation.--Notwithstanding any other provision of
this Act, for any fiscal year for which funds are authorized
to be appropriated under this Act that immediately follows a
fiscal year in which the Government has an actual on-budget
deficit and an actual off-budget surplus, the amount of money
authorized to be appropriated under this Act for the
Technology Innovation Program under section 28 of the
National Institute of Standards and Technology Act, as
amended by subsection (a) of this section, shall not exceed
the amount appropriated for that Program, or the predecessor
Advanced Technology Program, for the preceding fiscal year.
(2) Definitions.--For purposes of this subsection--
(A) the term ``actual on-budget deficit'' means a fiscal
year during which total outlays of the Government excluding
outlays from Social Security programs exceeds total receipts
of the Government excluding receipts from Social Security
programs;
(B) the term ``actual off-budget surplus'' means a fiscal
year in which receipts from Social Security programs exceeds
outlays from Social Security programs; and
(C) the term ``Social Security programs'' means the Federal
Old-Age and Survivors Insurance Trust Fund and the Federal
Disability Insurance Trust Fund.
Mr. WU. Mr. Speaker, I reserve a point of order against the motion to
recommit.
The SPEAKER pro tempore. A point of order is reserved.
The gentleman from Pennsylvania is recognized for 5 minutes.
Mr. ENGLISH of Pennsylvania. Mr. Speaker, in my view, there are three
Grand Canyons in America. One is famous, and it is in Arizona and, I
think, familiar to most in the West. Another is well known in the
eastern United States, and it is in Wellsboro, Pennsylvania.
The third has opened up since the last election. And here, Mr.
Speaker, I am referring to the grand canyon, the gap, between the
rhetoric of the Democratic Caucus in the House of Representatives, as
witnessed on the floor of the House in the last Congress and in
previous Congresses, and the policies of the Democratic Congress since
being sworn in in this Congress.
I remember, Mr. Speaker, fondly, some of the speeches that were given
on the floor of Congress on behalf of the Social Security system. Some
fierce, even lachrymose presentations that any additional funding for
any new priority inevitably would be at the expense of the balance of
the Social Security system, which is seriously in the red. In other
words, new spending, because we were running a deficit, was inevitably
at the expense of the Social Security system. I have heard our friends
on the other side of the aisle make the case repeatedly in previous
Congresses to restrict spending because additional funds would be
coming out of the Social Security system.
But, Mr. Speaker, since the election, Democrats seem to have muted
these concerns and Democratic actions have been very different.
Mr. Speaker, I propose to give our friends on the other side of the
aisle an opportunity to bridge the Grand Canyon. I propose to give the
majority a small, perhaps symbolic, but very important opportunity to
reach out and express their commitment to fiscal policies that preserve
the Social Security balance for what it was intended for: to fund
retirement savings.
Mr. Speaker, by commingling our Social Security surplus with our
deficit-ridden general fund, we potentially expose our Social Security
system to risk by shielding our policymakers from their spending
decisions to the full consequences and the full balance sheet. The time
has come for us to change that practice.
Specifically, this motion says that the funding authorized for the
Advanced Technology Program will be capped at the previous year's
appropriated amount until such time as the Social Security surplus is
not used to foot part of the bill.
There is no doubt that the ATP program has great merit. But I think
we have to ask ourselves, Mr. Speaker, is increasing funding for the
program more important than saving the Social Security surplus for
future beneficiaries?
Mr. Speaker, I serve on the committee of jurisdiction, and recently
we had an opportunity to hear from the Social Security actuaries one
more time that the Social Security system is at risk, is under enormous
pressure, and that the time has come to take decisive steps to make it
solvent so that its promise can be fulfilled to the next generation.
What we are proposing here today is maybe to begin this process in a
small way and create an opportunity for all of our friends in this
institution to go on record firmly in an important policy decision and
make it clear that we are not going to raid the Social Security fund in
the future.
This is a very clear issue. It is a very simple issue. It is an
opportunity to cut past the rhetoric and, frankly, create an
opportunity for us to do something very significant on one of the major
issues facing the country.
Mr. Speaker, I hope everyone in this body will join me in supporting
this very important initiative on behalf of the Social Security fund.
Mr. Speaker, I yield back the balance of my time.
Mr. WU. Mr. Speaker, I withdraw my point of order, and I rise in
strong opposition to the motion to recommit.
The SPEAKER pro tempore. The gentleman is recognized for 5 minutes.
Mr. WU. Mr. Speaker, we have heard much talk about the Social
Security trust fund and the solvency of Social Security. But in the
time that I have been here, in 8 years, the solvency of Social Security
has been increased by approximately 8 years, and that increase is
because of American economic growth. It was projected at 34 years of
solvency. It is currently projected at 42 years of solvency, and that
[[Page H4463]]
is based on conservative, conservative estimates. The reason why there
has been that increase in the solvency period of Social Security is
because of economic growth.
There is nothing more important to the American economy and our
competitiveness than the legislation that we are considering today.
The motion to recommit which the gentleman offers would fundamentally
gut this legislation and prevent us from investing in the most
productive of technologies, a traditional role which the Federal
Government has played to support research and early-stage development,
not commercialization, but early-stage development. By prohibiting
those activities with this cap, what in essence would happen is our
rate of economic growth would be slackened, our ability to manufacture
jobs would be decreased.
This is a motion to recommit which would gut the bill, and I urge its
defeat.
Mr. Speaker, I yield back the balance of my time.
The SPEAKER pro tempore. Without objection, the previous question is
ordered on the motion to recommit.
There was no objection.
The SPEAKER pro tempore. The question is on the motion to recommit.
The question was taken; and the Speaker pro tempore announced that
the noes appeared to have it.
Mr. ENGLISH of Pennsylvania. Mr. Speaker, on that I demand the yeas
and nays.
The yeas and nays were ordered.
The SPEAKER pro tempore. Pursuant to clause 9 of rule XX, the Chair
will reduce to 5 minutes the minimum time for any electronic vote on
the question of passage.
The vote was taken by electronic device, and there were--yeas 190,
nays 216, not voting 26, as follows:
[Roll No. 300]
YEAS--190
Aderholt
Akin
Alexander
Bachmann
Bachus
Baker
Barrett (SC)
Bartlett (MD)
Barton (TX)
Biggert
Bilbray
Bilirakis
Bishop (UT)
Blackburn
Blunt
Boehner
Bonner
Bono
Boozman
Boustany
Brady (TX)
Brown (SC)
Brown-Waite, Ginny
Buchanan
Burgess
Burton (IN)
Buyer
Calvert
Camp (MI)
Campbell (CA)
Cannon
Cantor
Capito
Carter
Castle
Chabot
Coble
Cole (OK)
Conaway
Crenshaw
Culberson
Davis (KY)
Davis, David
Davis, Tom
Deal (GA)
Dent
Diaz-Balart, L.
Diaz-Balart, M.
Donnelly
Doolittle
Drake
Dreier
Duncan
Ellsworth
Emerson
English (PA)
Everett
Fallin
Feeney
Ferguson
Flake
Forbes
Fortenberry
Fossella
Foxx
Frelinghuysen
Gallegly
Garrett (NJ)
Gerlach
Gilchrest
Gillmor
Gohmert
Goode
Goodlatte
Granger
Hall (TX)
Hastings (WA)
Hayes
Heller
Hensarling
Herger
Hill
Hobson
Hoekstra
Hulshof
Inglis (SC)
Issa
Johnson (IL)
Johnson, Sam
Jones (NC)
Jordan
Keller
King (IA)
King (NY)
Kingston
Kirk
Kline (MN)
Knollenberg
Kuhl (NY)
LaHood
Lamborn
Latham
LaTourette
Lewis (CA)
Lewis (KY)
Linder
LoBiondo
Lucas
Lungren, Daniel E.
Mack
Manzullo
Marchant
McCarthy (CA)
McCaul (TX)
McCotter
McCrery
McKeon
Mica
Miller (FL)
Miller (MI)
Miller, Gary
Moran (KS)
Murphy, Tim
Musgrave
Myrick
Neugebauer
Nunes
Pence
Peterson (PA)
Petri
Pickering
Pitts
Platts
Poe
Porter
Price (GA)
Pryce (OH)
Putnam
Ramstad
Regula
Rehberg
Reichert
Renzi
Reynolds
Rogers (AL)
Rogers (KY)
Rogers (MI)
Rohrabacher
Ros-Lehtinen
Roskam
Royce
Ryan (WI)
Sali
Saxton
Schmidt
Sensenbrenner
Sessions
Shadegg
Shays
Shimkus
Shuler
Shuster
Simpson
Smith (NE)
Smith (NJ)
Smith (TX)
Souder
Stearns
Sullivan
Taylor
Terry
Thornberry
Tiahrt
Tiberi
Turner
Upton
Walberg
Walden (OR)
Walsh (NY)
Wamp
Weldon (FL)
Weller
Westmoreland
Whitfield
Wicker
Wilson (NM)
Wilson (SC)
Wolf
Young (AK)
Young (FL)
NAYS--216
Abercrombie
Ackerman
Allen
Altmire
Andrews
Arcuri
Baca
Baird
Baldwin
Barrow
Bean
Becerra
Berkley
Berman
Berry
Bishop (GA)
Bishop (NY)
Blumenauer
Boren
Boswell
Boucher
Boyd (FL)
Boyda (KS)
Braley (IA)
Brown, Corrine
Capps
Capuano
Cardoza
Carnahan
Carney
Castor
Chandler
Clarke
Clay
Cleaver
Clyburn
Cohen
Conyers
Cooper
Costello
Courtney
Cramer
Crowley
Cuellar
Cummings
Davis (AL)
Davis (CA)
Davis (IL)
Davis, Lincoln
DeFazio
DeGette
Delahunt
DeLauro
Dicks
Dingell
Doggett
Doyle
Edwards
Ehlers
Ellison
Emanuel
Eshoo
Etheridge
Farr
Filner
Frank (MA)
Giffords
Gillibrand
Gonzalez
Gordon
Green, Al
Green, Gene
Grijalva
Gutierrez
Hall (NY)
Hare
Harman
Hastings (FL)
Herseth Sandlin
Higgins
Hinchey
Hinojosa
Hirono
Hodes
Holden
Holt
Honda
Hooley
Hoyer
Inslee
Israel
Jackson (IL)
Jackson-Lee (TX)
Jefferson
Johnson (GA)
Jones (OH)
Kagen
Kanjorski
Kaptur
Kennedy
Kildee
Kilpatrick
Kind
Klein (FL)
Kucinich
Langevin
Lantos
Larsen (WA)
Larson (CT)
Lee
Levin
Lewis (GA)
Lipinski
Loebsack
Lofgren, Zoe
Lowey
Lynch
Mahoney (FL)
Maloney (NY)
Markey
Marshall
Matheson
Matsui
McCarthy (NY)
McCollum (MN)
McDermott
McGovern
McIntyre
McNerney
McNulty
Meehan
Meek (FL)
Meeks (NY)
Melancon
Michaud
Miller (NC)
Miller, George
Mitchell
Mollohan
Moore (KS)
Moore (WI)
Moran (VA)
Murphy (CT)
Murphy, Patrick
Murtha
Nadler
Napolitano
Neal (MA)
Oberstar
Obey
Olver
Pallone
Pascrell
Pastor
Payne
Perlmutter
Peterson (MN)
Pomeroy
Price (NC)
Rahall
Rangel
Reyes
Rodriguez
Ross
Roybal-Allard
Ruppersberger
Rush
Ryan (OH)
Salazar
Sanchez, Linda T.
Sanchez, Loretta
Sarbanes
Schakowsky
Schiff
Schwartz
Scott (GA)
Scott (VA)
Serrano
Sestak
Shea-Porter
Sherman
Sires
Skelton
Slaughter
Smith (WA)
Snyder
Solis
Space
Spratt
Stark
Stupak
Sutton
Tauscher
Thompson (CA)
Thompson (MS)
Tierney
Towns
Udall (CO)
Udall (NM)
Van Hollen
Velazquez
Visclosky
Walz (MN)
Wasserman Schultz
Waters
Watson
Watt
Waxman
Weiner
Welch (VT)
Wexler
Wilson (OH)
Woolsey
Wu
Wynn
Yarmuth
NOT VOTING--26
Brady (PA)
Butterfield
Carson
Costa
Cubin
Davis, Jo Ann
Engel
Fattah
Franks (AZ)
Gingrey
Graves
Hastert
Hunter
Jindal
Johnson, E. B.
Lampson
McHenry
McHugh
McMorris Rodgers
Ortiz
Paul
Pearce
Radanovich
Rothman
Tancredo
Tanner
{time} 1505
Ms. BERKLEY, Mr. COHEN and Mr. JOHNSON of Georgia changed their vote
from ``yea'' to ``nay.''
Ms. ROS-LEHTINEN and Messrs. BILBRAY, KIRK, PICKERING, WOLF and
GILCHREST changed their vote from ``nay'' to ``yea.''
So the motion to recommit was rejected.
The result of the vote was announced as above recorded.
The SPEAKER pro tempore (Mr. Scott of Virginia). The question is on
the passage of the bill.
The question was taken; and the Speaker pro tempore announced that
the ayes appeared to have it.
Recorded Vote
Mr. WU. Mr. Speaker, I demand a recorded vote.
A recorded vote was ordered.
The SPEAKER pro tempore. This will be a 5-minute vote.
The vote was taken by electronic device, and there were--ayes 385,
noes 23, not voting 24, as follows:
[Roll No. 301]
AYES--385
Abercrombie
Ackerman
Aderholt
Alexander
Allen
Altmire
Andrews
Arcuri
Baca
Bachmann
Bachus
Baird
Baker
Baldwin
Barrow
Bartlett (MD)
Barton (TX)
Bean
Becerra
Berkley
Berman
Berry
Biggert
Bilbray
Bilirakis
Bishop (GA)
Bishop (NY)
Bishop (UT)
Blackburn
Blumenauer
Blunt
Boehner
Bonner
Bono
Boozman
Boren
Boswell
Boucher
Boustany
Boyd (FL)
Boyda (KS)
Brady (TX)
Braley (IA)
Brown (SC)
Brown, Corrine
Brown-Waite, Ginny
Buchanan
Burgess
Buyer
Calvert
Camp (MI)
Cannon
Capito
Capps
Capuano
Cardoza
Carnahan
Carney
Carson
Castle
Castor
Chabot
Chandler
Clarke
Clay
Cleaver
Clyburn
Cohen
Cole (OK)
Conaway
Conyers
Cooper
Costello
Courtney
Cramer
Crenshaw
Crowley
Cuellar
Culberson
Cummings
Davis (AL)
Davis (CA)
Davis (IL)
Davis (KY)
Davis, David
Davis, Lincoln
Davis, Tom
Deal (GA)
DeFazio
DeGette
Delahunt
DeLauro
Dent
Diaz-Balart, L.
Diaz-Balart, M.
Dicks
Dingell
Doggett
Donnelly
Doolittle
Doyle
Drake
Dreier
Edwards
Ehlers
Ellison
Ellsworth
Emanuel
Emerson
Eshoo
Etheridge
Everett
Fallin
Farr
Feeney
Ferguson
Filner
Forbes
Fortenberry
Fossella
Frank (MA)
Frelinghuysen
Gallegly
Garrett (NJ)
Gerlach
[[Page H4464]]
Giffords
Gilchrest
Gillibrand
Gillmor
Gingrey
Gohmert
Gonzalez
Goode
Goodlatte
Gordon
Granger
Green, Al
Green, Gene
Grijalva
Gutierrez
Hall (NY)
Hall (TX)
Hare
Harman
Hastings (FL)
Hastings (WA)
Hayes
Heller
Herger
Herseth Sandlin
Higgins
Hill
Hinchey
Hinojosa
Hirono
Hobson
Hodes
Hoekstra
Holden
Holt
Honda
Hooley
Hoyer
Hulshof
Inglis (SC)
Inslee
Israel
Issa
Jackson (IL)
Jackson-Lee (TX)
Jefferson
Johnson (GA)
Johnson (IL)
Jones (NC)
Jones (OH)
Jordan
Kagen
Kanjorski
Kaptur
Keller
Kennedy
Kildee
Kilpatrick
Kind
King (NY)
Kirk
Klein (FL)
Kline (MN)
Knollenberg
Kucinich
Kuhl (NY)
LaHood
Langevin
Lantos
Larsen (WA)
Larson (CT)
Latham
LaTourette
Lee
Levin
Lewis (CA)
Lewis (GA)
Lewis (KY)
Linder
Lipinski
LoBiondo
Loebsack
Lofgren, Zoe
Lowey
Lucas
Lungren, Daniel E.
Lynch
Mahoney (FL)
Maloney (NY)
Manzullo
Marchant
Markey
Marshall
Matheson
Matsui
McCarthy (CA)
McCarthy (NY)
McCaul (TX)
McCollum (MN)
McCotter
McCrery
McDermott
McGovern
McIntyre
McKeon
McNerney
McNulty
Meehan
Meek (FL)
Meeks (NY)
Melancon
Mica
Michaud
Miller (MI)
Miller (NC)
Miller, Gary
Miller, George
Mitchell
Mollohan
Moore (KS)
Moore (WI)
Moran (KS)
Moran (VA)
Murphy (CT)
Murphy, Patrick
Murphy, Tim
Murtha
Musgrave
Myrick
Nadler
Napolitano
Neal (MA)
Neugebauer
Nunes
Oberstar
Obey
Olver
Pallone
Pascrell
Pastor
Payne
Perlmutter
Peterson (MN)
Peterson (PA)
Petri
Pickering
Pitts
Platts
Poe
Pomeroy
Porter
Price (GA)
Price (NC)
Pryce (OH)
Putnam
Rahall
Ramstad
Rangel
Regula
Rehberg
Reichert
Renzi
Reyes
Reynolds
Rodriguez
Rogers (AL)
Rogers (KY)
Rogers (MI)
Rohrabacher
Ros-Lehtinen
Roskam
Ross
Roybal-Allard
Ruppersberger
Rush
Ryan (OH)
Ryan (WI)
Salazar
Sanchez, Linda T.
Sanchez, Loretta
Sarbanes
Saxton
Schakowsky
Schiff
Schmidt
Schwartz
Scott (GA)
Scott (VA)
Serrano
Sessions
Sestak
Shays
Shea-Porter
Sherman
Shimkus
Shuler
Shuster
Simpson
Sires
Skelton
Slaughter
Smith (NE)
Smith (NJ)
Smith (TX)
Smith (WA)
Snyder
Solis
Souder
Space
Spratt
Stark
Stearns
Stupak
Sullivan
Sutton
Tauscher
Taylor
Terry
Thompson (CA)
Thompson (MS)
Thornberry
Tiahrt
Tiberi
Tierney
Towns
Turner
Udall (CO)
Udall (NM)
Upton
Van Hollen
Velazquez
Visclosky
Walberg
Walden (OR)
Walsh (NY)
Walz (MN)
Wamp
Wasserman Schultz
Waters
Watson
Watt
Waxman
Weiner
Welch (VT)
Weldon (FL)
Weller
Westmoreland
Wexler
Whitfield
Wicker
Wilson (NM)
Wilson (OH)
Wilson (SC)
Wolf
Woolsey
Wu
Wynn
Yarmuth
Young (AK)
Young (FL)
NOES--23
Akin
Barrett (SC)
Burton (IN)
Campbell (CA)
Cantor
Carter
Coble
Duncan
English (PA)
Flake
Foxx
Franks (AZ)
Hensarling
Johnson, Sam
King (IA)
Kingston
Lamborn
Mack
Pence
Royce
Sali
Sensenbrenner
Shadegg
NOT VOTING--24
Brady (PA)
Butterfield
Costa
Cubin
Davis, Jo Ann
Engel
Fattah
Graves
Hastert
Hunter
Jindal
Johnson, E. B.
Lampson
McHenry
McHugh
McMorris Rodgers
Miller (FL)
Ortiz
Paul
Pearce
Radanovich
Rothman
Tancredo
Tanner
Announcement by the Speaker Pro Tempore
The SPEAKER pro tempore (during the vote). Members are advised 2
minutes remain in this vote.
{time} 1513
Mr. KING of Iowa changed his vote from ``aye'' to ``no.''
So the bill was passed.
The result of the vote was announced as above recorded.
A motion to reconsider was laid on the table.
Stated for:
Mr. MILLER of Florida. Mr. Speaker, I missed rollcall vote No. 301 on
May 3, 2007. It was a vote on H.R. 1868, the Technology Innovation and
Manufacturing Stimulation Act.
If present, I would have voted rollcall vote No. 301, ``aye.''
____________________